title: Bupropion-SR for smoking cessation in early recovery from alcohol dependence: a placebo-controlled, double-blind pilot study.
abstract: We conducted a double-blind pilot study involving 11 alcohol- and nicotine-dependent patients randomized to receive either bupropion or placebo. Four of six patients on bupropion and one of five patients on placebo were abstinent from smoking at the end of medication phase. Those in the bupropion group reported significantly less craving (p < .02) and less exposure to cigarette smoke over time (expired carbon monoxide; p < .01). There were no serious adverse events and no main effects of medication group on either per subject or total number of adverse events. All those who completed treatment remained abstinent from alcohol.
authors.affiliation: Department of Behavioral Science, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. maherkaram@mdanderson.org
authors.forename: Maher
authors.initials: M
authors.lastname: Karam-Hage
authors.forename: Stephen
authors.initials: S
authors.lastname: Strobbe
authors.forename: Jason D
authors.initials: JD
authors.lastname: Robinson
authors.forename: Kirk J
authors.initials: KJ
authors.lastname: Brower
mesh_terms: D000437:Alcoholism / Q000150:complications / Q000534:rehabilitation*; D016642:Bupropion / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D018765:Dopamine Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010865:Pilot Projects; D016540:Smoking Cessation / Q000379:methods*; D013695:Temperance; D013997:Time Factors; D014029:Tobacco Use Disorder / Q000150:complications / Q000534:rehabilitation*
chemical_list: D003692:Delayed-Action Preparations; D018765:Dopamine Uptake Inhibitors; D016642:Bupropion